THURSDAY: The Procter & Gamble community’s (that includes operations in approx. 70 countries worldwide) Gillette sues Dollar Shave Club in District of Delaware on the basis of a reason that razor blade delivery service’s razors violate Gillette’s exclusive rights. The suit seeks damages, and an injunction to block sales of products that infringe Gillette’s patented technology.
Dollar Shave Club is a Venice, California-based company that delivers razors and other personal grooming products straight to consumers by mail. The company positions itself as a cost-effective and convenient alternative to retail chains while P&G serves consumers all around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®.
For over 100 years, P&G’s Gillette business has been a clear innovation leader in the shaving category, revolutionizing the shaving experience time and again since the advent of the first safety razor. Today, Gillette offers consumers one of the best shaving experiences in the world with advanced razors like Fusion ProGlide. Not to mention, Gillette razors have also won accolades and endorsements from grooming experts, dermatologists and skin experts around the world. They are being used and recommended by 750 million people worldwide who prefer it to be highly durable.
“We have long invested heavily in innovation, and our talented scientists have dedicated their careers to delivering the best shaving experience possible for men and women around the world. Our patents help protect the many technical advancements we’ve made through the years – and when it becomes necessary, we take action to protect these important assets.” – P&G Chief Legal Officer Deborah Majoras.
On overviewing P&G’s Stock, it has remained unchanged but has lost 11% year to date while the Dow Jones Industrial Average has slipped by approx. 0.4%.
